## Benjamin W Fischer-Valuck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8305605/publications.pdf

Version: 2024-02-01

57 papers

1,519 citations

411340 20 h-index 38 g-index

57 all docs

57 docs citations

57 times ranked

2507 citing authors

#	Article	IF	CITATIONS
1	Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 123-131.	0.9	2
2	Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer. Brachytherapy, 2022, , .	0.2	1
3	Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. European Urology Open Science, 2022, 37, 80-89.	0.2	2
4	Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy. European Urology Oncology, 2022, 5, 246-250.	2.6	5
5	Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 343-350.e4.	2.3	0
6	Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. Clinical Genitourinary Cancer, 2021, 19, 41-46.e1.	0.9	7
7	Stereotactic body radiation therapy use for high risk prostate cancer in the United States. Prostate Cancer and Prostatic Diseases, 2021, 24, 578-581.	2.0	2
8	Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma. JAMA Dermatology, 2021, 157, 540.	2.0	19
9	Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer. Brachytherapy, 2021, 20, 1130-1138.	0.2	3
10	Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2021, 19, 362-368.	0.9	12
11	Association of race with receipt of definitive therapy for high risk prostate cancer in older men. Journal of Geriatric Oncology, 2021, , .	0.5	1
12	Influence of Timing between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients with Localized, High-Risk Prostate Cancer. Advances in Radiation Oncology, 2021, 6, 100803.	0.6	3
13	Reply to: Dose-escalation of radiation may improve outcomes of squamous cell carcinoma of bladder. Clinical and Translational Radiation Oncology, 2020, 20, 52.	0.9	O
14	Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer. Radiation Oncology, 2020, 15, 217.	1.2	6
15	Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. Brachytherapy, 2020, 19, 557-566.	0.2	1
16	Challenges in Re-Irradiation in the Thorax: Managing Patients with Locally Recurrent Non-Small Cell Lung Cancer. Seminars in Radiation Oncology, 2020, 30, 223-231.	1.0	7
17	Analysis of Radiation Facility Volume and Survival in Men With Lymph Node–Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy. JAMA Network Open, 2020, 3, e2025143.	2.8	5
18	Patterns of care and survival outcomes for laryngeal small cell cancer. Head and Neck, 2019, 41, 722-729.	0.9	2

#	Article	IF	CITATIONS
19	Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma. Frontiers in Oncology, 2019, 9, 922.	1.3	32
20	Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer. Journal of Contemporary Brachytherapy, 2019, 11, 320-328.	0.4	8
21	Magnetic Resonance Image Guided Stereotactic Body Radiation Therapy to the Primary Renal Mass in Metastatic Renal Cell Carcinoma. Advances in Radiation Oncology, 2019, 4, 566-570.	0.6	8
22	A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database. Clinical and Translational Radiation Oncology, 2019, 15, 38-41.	0.9	17
23	Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Medicine, 2019, 8, 3698-3709.	1.3	12
24	Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning: An ASTRO Consensus Paper. Practical Radiation Oncology, 2019, 9, 65-72.	1.1	49
25	Impact of Facility Radiation Patient Volume on Overall Survival in Patients with Muscle Invasive Bladder Cancer Undergoing Trimodality Bladder Preservation Therapy. Bladder Cancer, 2019, 5, 235-244.	0.2	6
26	A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate. Frontiers in Oncology, 2019, 9, 1378.	1.3	20
27	Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability. Practical Radiation Oncology, 2019, 9, 5-8.	1.1	9
28	Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 471-475.	0.6	20
29	Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology, 2018, 8, e7-e15.	1.1	43
30	Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. Journal of Urology, 2018, 199, 416-423.	0.2	36
31	Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. European Urology Focus, 2018, 4, 900-906.	1.6	30
32	Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter?. Bladder Cancer, 2018, 4, 311-317.	0.2	2
33	Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Radiotherapy and Oncology, 2018, 128, 266-273.	0.3	48
34	Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospitalâ€based analysis of patterns of care, RT fractionation scheme, and overall survival. Cancer Medicine, 2018, 7, 4240-4250.	1.3	10
35	Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database. Journal of Neuro-Oncology, 2017, 132, 109-117.	1.4	27
36	Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results ofÂaÂPhase III Trial. International Journal of Radiation Oncology Biology Physics, 2017, 97, 976-985.	0.4	276

#	Article	IF	Citations
37	Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system. Advances in Radiation Oncology, 2017, 2, 485-493.	0.6	128
38	Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the <scp>N</scp> ational <scp>C</scp> ancer <scp>D</scp> atabase. Cancer, 2017, 123, 682-687.	2.0	56
39	Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Practical Radiation Oncology, 2017, 7, 195-202.	1.1	62
40	The world's first single-room proton therapy facility: Two-year experience. Practical Radiation Oncology, 2017, 7, e71-e76.	1.1	21
41	Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case. Practical Radiation Oncology, 2017, 7, e23-e26.	1.1	2
42	An integrated model-driven method for in-treatment upper airway motion tracking using cine MRI in head and neck radiation therapy. Medical Physics, 2016, 43, 4700-4710.	1.6	14
43	Magnetic Resonance Image Guided Radiation Therapy (MR-IGRT) for the Treatment of Prostate Cancer: Initial Clinical Experience and Patient Selection. International Journal of Radiation Oncology Biology Physics, 2016, 96, E278.	0.4	O
44	Magnetic Resonance Image Guided Radiation Therapy for External Beam Accelerated Partial-Breast Irradiation: Evaluation of Delivered Dose and Intrafractional Cavity Motion. International Journal of Radiation Oncology Biology Physics, 2016, 96, 785-792.	0.4	73
45	Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. International Journal of Radiation Oncology Biology Physics, 2016, 94, 394-403.	0.4	245
46	SIFT-based dense pixel tracking on 0.35 T cine-MR images acquired during image-guided radiation therapy with application to gating optimization. Medical Physics, 2015, 43, 279-293.	1.6	34
47	Comparison of Stereotactic Body Radiation Therapy for Biopsy-Proven versus Radiographically Diagnosed Early-Stage Non-Small Lung Cancer: A Single-Institution Experience. Tumori, 2015, 101, 287-293.	0.6	12
48	Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 93, 649-657.	0.4	34
49	SU-F-303-11: Implementation and Applications of Rapid, SIFT-Based Cine MR Image Binning and Region Tracking. Medical Physics, 2015, 42, 3540-3540.	1.6	1
50	Prognostic utility of serial PET/CT imaging following stereotactic body radiation therapy (SBRT) in early stage lung cancer: a single institution experience. Journal of Radiation Oncology, 2014, 3, 379-386.	0.7	2
51	Helical Image-guided Stereotactic Body Radiotherapy (SBRT) for the Treatment of Earlystage Lung Cancer: A Single-institution Experience at the Willis-Knighton Cancer Center. Tumori, 2014, 100, 42-48.	0.6	11
52	Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center. Tumori, 2014, 100, 42-8.	0.6	9
53	Influence of patient characteristics on survival following treatment with helical stereotactic body radiotherapy (SBRT) in stage I nonâ€smallâ€cell lung cancer. Thoracic Cancer, 2013, 4, 27-34.	0.8	9
54	Regulating in Vitro Motility of Human Mesenchymal Stem Cells with Macrophage Migration Inhibitory Factor (MIF) and a Small-Molecule MIF Antagonist., 2012,, 149-160.		0

#	Article	IF	CITATIONS
55	Activation of CD74 inhibits migration of human mesenchymal stem cells. In Vitro Cellular and Developmental Biology - Animal, 2010, 46, 566-572.	0.7	26
56	Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnology Letters, 2010, 32, 19-27.	1.1	27
57	Small-Molecule Antagonist of Macrophage Migration Inhibitory Factor Enhances Migratory Response of Mesenchymal Stem Cells to Bronchial Epithelial Cells. Tissue Engineering - Part A, 2009, 15, 2335-2346.	1.6	22